Key result
Naftopidil significantly improved the mean International Prostate Symptoms Score at 30 days compared to tamsulosin (5.67 vs 6.47, p=0.005) in men with benign prostatic enlargement.
Why the study?
Does naftopidil improve uroflowmetry, post-void residue, and International Prostate Symptoms Score compared to tamsulosin in men with benign prostatic enlargement?
RCT (n=60)
Odd/even days
No
Does naftopidil improve uroflowmetry, post-void residue, and International Prostate Symptoms Score compared to tamsulosin in men with benign prostatic enlargement?
Naftopidil may provide better overall objective improvement and relief of irritative symptoms compared to tamsulosin in men with benign prostatic enlargement over a 30-day period.
Supports naftopidil preference for short-term symptom relief in BPE; extends RCT data on alpha-blocker selection.
INTRODUCTION: Lower urinary tract symptoms in men, over age of 50 years is suggestive of benign prostatic enlargement (BPE). Different alpha-blockers have been evaluated for the treatment of benign prostatic hyperplasia for over last 30 years. This study was conducted in a tertiary care institution during the period of year between June 2011 and August 2013 to compare the effect of naftopidil and tamsulosin in reducing the obstructive and irritable symptoms of BPE. SUBJECTS AND METHODS: A prospective randomized comparative study was carried on 60 patients of BPE by assigning half of them to treatment with tamsulosin and rest with naftopidil. Pre- and post-treatment uroflowmetry (UFM), post-void residue (PVR), International Prostate Symptoms Score (IPSS), were obtained at 15 and 30 days after starting treatment. RESULTS: The age of patients ranged from 51 to 78. At base line there was no statistical difference between UFM parameter, PVR and IPSS in the two groups. UFM and PVR showed significantly better response at both intervals with naftopidil. Comparison of IPSS showed better improvement in Group A both at 15 and 30 days. It was seen that the obstructive symptoms showed a significantly better response with tamsulosin and symptoms of irritability was seen better response with naftopidil. CONCLUSION: It was seen that during the period of follow-up of 30 days naftopidil had a better effect on UFM, PVR, IPSS compared with tamsulosin. In general, obstructive symptoms showed better improvement in tamsulosin and irritative symptoms showed better improvement in naftopidil.
No takes yet. Share an insight, caveat, or question.
Perumal et al. (2015) conducted an RCT in Benign prostatic enlargement (n=60). Naftopidil vs. Tamsulosin hydrochloride 0.4 mg once a day was evaluated on Mean International Prostate Symptoms Score (IPSS) at 30 days (p=0.005). Naftopidil significantly improved the mean International Prostate Symptoms Score at 30 days compared to tamsulosin (5.67 vs 6.47, p=0.005) in men with benign prostatic enlargement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: